The Mediterranean diet increases glucagon-like peptide 1 and oxyntomodulin compared with a vegetarian diet in patients with type 2 diabetes: A randomized controlled cross-over trial

What Was Tested

The paper reports a study of Oxyntomodulin, published as a randomized controlled trial.

To compare a Mediterranean diet (MED) with a high-fibre vegetarian diet (HFV) in terms of hunger-satiety perception through post-prandial assessment of appetite-related hormones glucagon-like peptide 1 (GLP-1) and oxyntomodulin, as well as self-rated visual analogue scale (VAS) quantification, in overweight/obese subjects with type 2 diabetes (T2D).

Who Took Part

The age groups tagged for this paper are middle-aged adults and older adults, both men and women.

Twelve T2D subjects (Male to female ratio = 7:5), mean age 63 ± 8.5 years, were enrolled in a randomized, controlled, crossover study.

Participants consumed an MED meal as well as an isocaloric meal rich in complex carbohydrate as well as an isocaloric MED meal in two different visits with a 1-week washout period between the two visits.

How the Study Was Run

The researchers set it up as a randomized and crossover study.

The participants were allocated by chance, so the Oxyntomodulin group and the comparison group should start out alike.

Each person switched between Oxyntomodulin and the comparison at some point, usually with a gap in between.

Appetite ratings, glucose/insulin, and gastrointestinal hormone concentrations were measured at fasting and every 30' until 210' following meal consumption.

What Was Measured

PubMed files the paper under topics including Blood Glucose, Diabetes Mellitus, Type 2, Diet, Mediterranean, Diet, Vegetarian, Glucagon-Like Peptide 1, Glucose and Insulin.

Author keywords: GLP-1, appetite control, dietary intervention, incretin physiology, obesity therapy and type 2 diabetes.

What This Means in Plain Language

The paper is a randomized and crossover study of Oxyntomodulin.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2021 (Diabetes/metabolism research and reviews), a journal based in England.

More context: the Oxyntomodulin compound page, all human trials.